Open Access

[Corrigendum] Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study

  • Authors:
    • Yoshiyuki Yamaguchi
    • Yousuke Katata
    • Fuminori Sano
    • Hiroaki Tanioka
    • Makoto Okawaki
    • Masahiro Yamamura
    • Takeshi Nagasaka
  • View Affiliations

  • Published online on: November 25, 2021     https://doi.org/10.3892/mco.2021.2454
  • Article Number: 20
  • Copyright : © Yamaguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Subsequently to the publication of this article, the authors wish to change the information that is presented in relation to the Research Ethics Committee and approval number for their prospective study, which is no longer accurated as reported. The final sentence in the ‘Study design’ subsection of the Patients and methods, as featured on p. 2 [‘This prospective study was reviewed about science and ethics and approved by the Research Ethics Committee of Kawasaki Medical School and Hospital (approval no. 240, UMIN000021797)]’ should be amended to the following: ‘This prospective study was reviewed for its science and ethics and approved by the Certified Committee for Regenerative Medicine of Kawasaki Medical School Hospital (Committee number, NB6150002; protocol number, PC6150017; Japan Registry of Clinical Trials [jRCT] number, jRCTc060190032’. Likewise, the first sentence in the ‘Ethics approval and consent to participate’ section of the Declarations on p. 7 should now read as follows: ‘The present study was reviewed and approved by the Certified Committee for Regenerative Medicine of Kawasaki Medical School Hospital (Committee number, NB6150002; protocol number, PC6150017; Japan Registry of Clinical Trials [jRCT] number, jRCTc060190032’. The authors apologize to the readership of the Journal for any inconvenience caused. [the original article was published in Molecular and Clinical Oncology 13: Article no. 55, 2020; DOI: 10.3892/mco.2020.2125]

Related Articles

Journal Cover

January-2022
Volume 16 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamaguchi Y, Katata Y, Sano F, Tanioka H, Okawaki M, Yamamura M and Nagasaka T: [Corrigendum] Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study. Mol Clin Oncol 16: 20, 2022
APA
Yamaguchi, Y., Katata, Y., Sano, F., Tanioka, H., Okawaki, M., Yamamura, M., & Nagasaka, T. (2022). [Corrigendum] Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study. Molecular and Clinical Oncology, 16, 20. https://doi.org/10.3892/mco.2021.2454
MLA
Yamaguchi, Y., Katata, Y., Sano, F., Tanioka, H., Okawaki, M., Yamamura, M., Nagasaka, T."[Corrigendum] Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study". Molecular and Clinical Oncology 16.1 (2022): 20.
Chicago
Yamaguchi, Y., Katata, Y., Sano, F., Tanioka, H., Okawaki, M., Yamamura, M., Nagasaka, T."[Corrigendum] Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study". Molecular and Clinical Oncology 16, no. 1 (2022): 20. https://doi.org/10.3892/mco.2021.2454